Exchange: NASDAQ·Updated 07:30 PM EST

COLL News

News
all
press releases
COLL or SDZNY: Which Is the Better Value Stock Right Now?
COLL vs. SDZNY: Which Stock Is the Better Value Option?
Zacks
COLL or SDZNY: Which Is the Better Value Stock Right Now?
COLL vs. SDZNY: Which Stock Is the Better Value Option?
Zacks
More News
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
Zacks
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
Zacks
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Barclays lowered their price target on shares of Collegium Pharmaceutical from $48.00 to $41.00 and set an "overweight" rating on the stock in a report on Monday...
MarketBeat
NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.
Zacks
uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.
Zacks
Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.
Zacks
PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.
Zacks
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.
Zacks

Advertisement|Remove ads.